Ticker brief
BMEA BIOMEA FUSION INC
Consumer, Non-cyclical · Biotechnology
last close
$0.6001
1 day
+2.6%
14 days
-57.7%
mkt cap
·
signals 14d
16
authors 14d
10
crowd 14d
-0.0σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-16 · now +0.27 (−1 bearish … +1 bullish)
Who spoke10
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 3 | +0.08 |
| @PrismMarketView | C | · | 3 | -0.40 |
| @Briefingcom | B | -2.26 | 2 | +0.10 |
| @PrismDM | A | -2.76 | 2 | -0.25 |
| @CHItrader | B | -0.22 | 1 | +0.40 |
| @AlertsAndNews | C | -3.92 | 1 | +0.00 |
| @zohmbastic | C | -2.94 | 1 | +0.00 |
| @BioStocks | C | -1.77 | 1 | +0.00 |
| @BPharmCatalyst | C | · | 1 | +0.45 |
| @Tickeron | C | +1.53 | 1 | +0.25 |
Recent signals16of 16 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @PrismDM | +0.20 | The tweet reports intraday price moves for five MedTech and biotech stocks. | -30.9% | tweet ↗ |
| 2026-10-16 | @PrismMarketView | +0.35 | Reports quantified intraday moves and volume across five stocks. | -30.9% | tweet ↗ |
| 2026-10-15 | @Tickeron | +0.25 | BMEA has clinical catalysts while YRD faces investigation-linked governance risk. | -28.3% | tweet ↗ |
| 2026-10-14 | @PrismMarketView | -0.85 | Quantifies a broad selloff and identifies the session's largest single-stock gainers and decliners | -28.0% | tweet ↗ |
| 2026-10-14 | @PrismDM | -0.70 | The tweet reports intraday percentage and price moves for four identifiable stocks. | -28.0% | tweet ↗ |
| 2026-10-14 | @PrismMarketView | -0.70 | Midday mover list reports large gains and losses. | -28.0% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.15 | Biomea announced Phase 1 results for oral GLP-1 candidate BMF-650. | -52.4% | tweet ↗ |
| 2026-10-13 | @BPharmCatalyst | +0.45 | Reports favorable Phase 1 weight-loss and safety results for BMF-650. | -52.4% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 1 BMF-650 diabetes and obesity results. | -52.4% | tweet ↗ |
| 2026-10-13 | @Briefingcom | +0.00 | Biomea scheduled release of Phase I BMF-650 clinical results for October 13. | -52.4% | tweet ↗ |
| 2026-10-13 | @Briefingcom | +0.20 | Lists the largest premarket gaps, led by SCNI up 59.5% and SNDX down 10.4%. | -52.4% | tweet ↗ |
| 2026-10-12 | @BioStocks | +0.00 | Announces a Tuesday date for Phase I GLP-131 data. | -55.9% | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.10 | Company will announce Phase 1 results for its oral GLP-1 candidate. | -55.9% | tweet ↗ |
| 2026-10-12 | @zohmbastic | +0.00 | Provides the scheduled date and time for release of Phase I clinical results. | -55.9% | tweet ↗ |
| 2026-10-12 | @AlertsAndNews | +0.00 | Gives the date and time for Biomea's Phase I data release and webcast. | -55.9% | tweet ↗ |
| 2026-10-07 | @CHItrader | +0.40 | Lists new analyst coverage for multiple stocks; extraction is capped at the first six. | -54.5% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.